Edgewise Therapeutics, Inc. EWTX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Edgewise Therapeutics, Inc. (EWTX) reported unrealized gains (losses) on available-for-sale securities of -$929K in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 4789.5% year-over-year, from -$19K to -$929K.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Edgewise Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities has grown at a -26.1% compound annual growth rate (CAGR), from -$514K to $281K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the unrealized fluctuations in the fair market value of the company's investment portfolio, specifically securities classified as available-for-sale. It reflects the impact of market volatility on the company's liquid assets that have not yet been sold. Tracking this provides transparency into the potential volatility of the company's balance sheet and the performance of its treasury investment strategy.